- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04659304
Study Evaluating Safety and Tolerability of Allocetra-OTS in Patients With COVID-19
A Multi-Center , Sequential Dose Escalation Study, Evaluating Safety and Tolerability of Allocetra-OTS in Patients With COVID-19
Study Overview
Detailed Description
Potential patients, who will be identified as suffering from moderate COVID-19 (as set forth in the FDA guidance for industry dated May 2020) will be recruited.
After the patient has signed the Informed Consent Form (ICF), and after confirmation that the patient meets all eligibility criteria, the patient will be enrolled to the relevant dose group according to the following sequential design:
Single Intravenous (IV) dose of Allocetra-OTS with 5x10^9 cells, Single Intravenous (IV) dose of Allocetra-OTS with 10x10^9 cells, Two IV doses of Allocetra-OTS with10x10^9 cells each dose (separated by 72 hours).
Each dose cohort will consist of 3 and up to 6 patients. In each dose cohort, starting with dose cohort 1, a single patient will be enrolled and dosed. If no dose limiting toxicity (DLT) is observed after at least 1 week and following review of relevant safety data of the first patient in that cohort by the DMC, 2 additional patients will be enrolled.
If no DLT is seen in the initial 3 dosed patients within a certain cohort and following DMC review, the first patient in the next dose cohort can be enrolled, repeating the same sequence of enrollment as described above.
If 1 DLT is seen in the initial 3 dosed patients within a certain cohort, the cohort will be expanded to a total of 6 patients. If >2/6 patients experience a DLT, the MTD will be reached. If no more than 1 patient out of 6 experiences a DLT, the next sequence of enrollment will be continued.
DMC will review and assess safety data at the predefined timepoints to recommend on cohort expansion or cohort escalation.
Investigational Product (IP) administration will occur on Day 1 within 12±4 hours from the time of eligibility.
Following IP administration (Day 1), patients will be followed for safety and efficacy assessments through 6 months.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Odelia Ben Shitrit, MBA
- Phone Number: 972-548887609
- Email: odelia@enlivexpharm.com
Study Contact Backup
- Name: Lior Binder
- Phone Number: 972-548054899
- Email: lior@enlivexpharm.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female > 18 and < 80 years of age.
- Laboratory confirmation of SARS-CoV-2 infection by RT-PCR from any diagnostic sampling source.
- Patient hospitalized due to COVID-19 in the last 24 hours.
Hospitalized patients meeting the criteria for moderate COVID-19, as set forth by the May 2020 FDA Guidance for Industry: COVID-19: Developing Drugs and Biological Products for Treatment or Prevention, Patients with symptoms of moderate illness with COVID-19, which could include any symptom of mild illness (such as fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, without shortness of breath or dyspnea) or shortness of breath with exertion with at least one of the following clinical signs:
- Respiratory rate: ≥ 20 breaths/minute;
- SpO2: > 93% on room air at sea level;
- Heart rate: ≥ 90 beats/minute;
- Signed written informed consent by the patient.
- Women and men who are of childbearing potential, willing to use acceptable contraceptive measures during 4 weeks from enrolment .
Exclusion Criteria:
Any signs indicative of Severe or Critical Illness Severity requiring hospitalization as defined below:
Severe COVID-19: Shortness of breath in rest, or respiratory distress, or respiratory rate (RR≥30 per minute , or heart rate (HR) ≥125 bpm, or SpO2≤93% on room air at sea level or PaO2/FiO2<300
Critical COVID-19- at least one of the following:
- Respiratory failure required at least one of the following: mechanical ventilation, oxygen delivered by high-flow nasal cannula, noninvasive positive pressure ventilation, ECMO.
- Shock
- Multi-organ dysfunction/failure.
- Women who are pregnant or breast feeding.
- Weight <50 kg or >110 kg.
- Stage 4 and 5 severe chronic kidney disease or requiring dialysis with eGFR < 30 ml/min.
- Patients with active malignant tumor.
- Patients who are participating in other concurrent investigational clinical trials or have been treated with any experimental agents within 30 days prior to enrollment.
Known active chronic viral infections including, but not limited to, active HBV, HCV, or HIV/AIDS or other chronic infections.
Based on medical history and concomitant therapies that would suggest infection, have suspected clinical diagnosis of current active TB or, if known, latent TB treated for less than 4 weeks with appropriate anti-TB therapy per institutional guidelines; Based on medical history and concomitant therapies that would suggest infection, suspected serious, active bacterial, fungal, viral (including, but not limited to, active HBV, HCV, or HIV/AIDS).
- Known immunocompromised state or immunosuppressing medications taken for indications other than SARS-CoV-2 (i.e., agents including chronic corticosteroids > 10 mg/day, azathioprine, cyclosporine, cyclophosphamide).
- Known New York Heart Association (NYHA) class III and IV heart failure or unstable angina, ventricular arrhythmias, active ischemic heart disease , or myocardial infarction within six months prior to diagnosis of COVID-19.
- Known active upper gastrointestinal (GI) tract ulceration or hepatic dysfunction including but not limited to biopsy-proven cirrhosis; end-stage cirrhosis (Child Pugh Class C); portal hypertension; episodes of past upper GI bleeding attributed to portal hypertension; or prior episodes of hepatic failure, encephalopathy, or coma.
- Patients with Glasgow Coma Scale (GCS) <13 with verbal score <5.
- Estimated GFR < 25 ml/min.
- Hemoglobin < 8 gr%.
Patients with history of chronic liver disease, evidence of acute cholangitis or cholecystitis. Patients with at least one of the following:
- ALT or AST > 5X ULN (upper limit of normal range)
- Bilirubin > 3 X ULN
- Combination of ALT/AST > 3 X ULN and elevated direct bilirubin>ULN
- Known history of transfusion reactions, hemolytic anemia, or allergic reaction.
- Organ allograft or previous history of stem cell transplantation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Cohort 1
Single Intravenous (IV) dose of Allocetra-OTS with 5x10^9 cells
|
Cell-based therapy comprised of allogeneic non-HLA matched peripheral blood mononuclear cells induced to an early apoptotic state.
|
Active Comparator: Cohort 2
Single Intravenous (IV) dose of Allocetra-OTS with 10x10^9 cells
|
Cell-based therapy comprised of allogeneic non-HLA matched peripheral blood mononuclear cells induced to an early apoptotic state.
|
Active Comparator: Cohort 3
Two IV doses of Allocetra-OTS with 10x10^9 cells in each dose
|
Cell-based therapy comprised of allogeneic non-HLA matched peripheral blood mononuclear cells induced to an early apoptotic state.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety - Adverse Events
Time Frame: 28 days
|
Number and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs).
|
28 days
|
Maximum Tolerated Dose (MTD)
Time Frame: 28 days
|
The highest dose of Allocetra-OTS that did not cause a Dose-Limiting Toxicity (DLT) in 2/6 cohort patientsor maximally administered dose if no DLT is seen.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy - PaO2 or SO2/FiO2 Ratio
Time Frame: 28 days
|
Change in PaO2 or SO2/FiO2 Ratio
|
28 days
|
Efficacy - mortality
Time Frame: 28 days
|
All-cause mortality
|
28 days
|
Efficacy - organ function / support measurements
Time Frame: 28 days
|
Oxygen free days, vasopressors free days, cumulative days in ICU or IMU
|
28 days
|
Efficacy - NEWS2 Score
Time Frame: 28 days
|
Change from baseline in National Early Warning Score 2 (NEWS2)
|
28 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Oren Hershkovitz, PhD, Enlivex Therapeutics R&D
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ENX-CL-03-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on Allocetra-OTS
-
Enlivex Therapeutics RDO Ltd.Terminated
-
Amir OronEnlivex Therapeutics Ltd.RecruitingKnee OsteoarthritisIsrael
-
Enlivex Therapeutics Ltd.Cato Research; Accelsiors CRO & Consultancy ServicesActive, not recruitingSepsis | Intraabdominal Infections | Cholecystitis, Acute | Urinary Tract Infections | Community-acquired Pneumonia | Cholangitis AcuteNetherlands, Israel, France, Belgium, Spain
-
Hadassah Medical OrganizationTel-Aviv Sourasky Medical Center; Barzilai Medical CenterUnknown
-
Enlivex Therapeutics Ltd.CompletedOrgan Dysfunction Syndrome SepsisIsrael
-
Enlivex Therapeutics RDO Ltd.TerminatedSolid Tumor | Peritoneal Cancer | Peritoneal MetastasesIsrael, Spain
-
RHEACELL GmbH & Co. KGRecruiting
-
RHEACELL GmbH & Co. KGRecruitingEpidermolysis BullosaUnited States